F. Andre explains why target prioritisation is important and describes attempts for guidance on how to use genomic data in oncology. The goal is an evidence-based definition of which molecular alterations should lead to treatment decision in daily practice, which ones could lead to driving patients to phase I/II trials, and which ones should not be used for treatment decision.